You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Moodys
Merck
Harvard Business School

Last Updated: December 4, 2023

Details for Patent: 8,216,560


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,216,560 protect, and when does it expire?

Patent 8,216,560 protects VELTASSA and is included in one NDA.

This patent has ninety-six patent family members in seventeen countries.

Summary for Patent: 8,216,560
Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han Ting (Livermore, CA), Fordtran; John (Dallas, TX), Klaerner; Gerrit (San Jose, CA), Buysse; Jerry M. (Los Altos, CA), Alpern; Robert (Dallas, TX), Liu; Mingjun (Campbell, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/055,726
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,216,560
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Recent additions to Drugs Protected by US Patent 8,216,560

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER 205739 Oct 2, 2023 RX Yes ⤷  Try a Trial ⤷  Try a Trial U-1766 TREATMENT OF HYPERKALEMIA
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER 205739 Oct 21, 2015 RX Yes ⤷  Try a Trial ⤷  Try a Trial U-1766 TREATMENT OF HYPERKALEMIA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,216,560

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF HYPERKALEMIA ⤷  Try a Trial
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF HYPERKALEMIA ⤷  Try a Trial
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF HYPERKALEMIA ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,216,560

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 453383 ⤷  Try a Trial
Austria 460927 ⤷  Try a Trial
Australia 2005228696 ⤷  Try a Trial
Australia 2005231383 ⤷  Try a Trial
Australia 2005231424 ⤷  Try a Trial
Australia 2010214729 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Johnson and Johnson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.